serabelisib

Home
Ligands
serabelisib

Ligand id: 8969

Name: serabelisib

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	6
Hydrogen bond donors	1
Rotatable bonds	3
Topological polar surface area	98.89
Molecular weight	363.13
XLogP	1.65
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Summary
Biological activity
Clinical data
References
Structure
Similar ligands

No information available.

No information available.

Summary of Clinical Use
A Phase 2 clinical trial assessing serabelisib (which has variably been known as INK-1117, MLN1117 and TAK-117) with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; NCT02393209) was terminated due to a lack of efficacy of this drug combination. Various Phase 1 and 2 trials with different drug combinations and in different tumour types are ongoing as of October 2018. Click here to link to ClinicalTrials.gov's full list of serabelisib trials.

Summary of Clinical Use

A Phase 2 clinical trial assessing serabelisib (which has variably been known as INK-1117, MLN1117 and TAK-117) with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; NCT02393209) was terminated due to a lack of efficacy of this drug combination. Various Phase 1 and 2 trials with different drug combinations and in different tumour types are ongoing as of October 2018. Click here to link to ClinicalTrials.gov's full list of serabelisib trials.